



Brazilian Journal of OTORHINOLARYNGOLOGY

www.bjorl.org



ORIGINAL ARTICLE

AIM2 inflammasome activation may mediate high mobility group box 1 release in murine allergic rhinitis



Yan Wang ^{ID a}, Shan Chen ^{ID a}, Ping-Li Yang ^{ID b}, Jian-Jun Chen ^{ID a}, Wei-Jia Kong ^{ID a,c,*}, Yan-Jun Wang ^{ID a,c,*}

^a Huazhong University of Science and Technology, Tongji Medical College, Union Hospital, Department of Otorhinolaryngology, Wuhan, China

^b Shihezi University School of Medicine, The First Affiliated Hospital, Department of Otorhinolaryngology, Shihezi, China

^c Huazhong University of Science and Technology, Tongji Medical College, Union Hospital, Institute of Otorhinolaryngology, Wuhan, China

Received 6 November 2020; accepted 22 December 2020

Available online 15 February 2021

KEYWORDS

AIM2;
Nlrp3;
Caspase-1;
Inflammasome;
Allergic rhinitis;
Pyroptosis

Abstract

Introduction: High mobility group box 1 protein participates in the pathogenesis of allergic rhinitis. Activation of the inflammasome can mediate the release of high mobility group box 1. The role of the absent in melanoma 2 inflammasome in allergic rhinitis remains unclear.

Objective: This study aimed to investigate the function of absent in melanoma 2 inflammasome in murine allergic rhinitis and the interaction between high mobility group box 1 and the absent in melanoma 2 inflammasome.

Methods: A murine allergic rhinitis model was established using twenty Balb/c mice. Expression of the components of the absent in melanoma 2 inflammasome: absent in melanoma 2, apoptosis-associated speck-like protein containing a CARD (Asc), caspase-1 p20, and additional nod-like receptor family pyrin domain containing 3 (Nlrp3) were detected by western blotting during allergic rhinitis. Alterations of absent in melanoma 2, caspase-1, and high mobility group box 1 after ovalbumin challenge were demonstrated by immunohistochemistry. TdT-mediated dUTP Nick end labeling, TUNEL assay, and cleavage of caspase-3 and PARP-1 were used for the observation of pyroptosis.

Results: Eosinophilia and goblet cell infiltration were observed in the nasal mucosa of mice in the allergic rhinitis group. Absent in melanoma 2, Asc, and caspase-1 p20 increased after ovalbumin exposure while Nlrp3 did not. High mobility group box 1 was released in the nasal mucosa of allergic rhinitis mice. TUNEL-positive cells increased in the epithelium and laminae propria, whereas cleavage of caspase-3 and PARP-1 was not observed.

* Corresponding authors.

E-mails: entwjkong@hust.edu.cn (W. Kong), yjwang@hust.edu.cn (Y. Wang).

Peer Review under the responsibility of Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial.

Conclusions: The absent in melanoma 2 inflammasome was activated and pyroptosis may occur in the nasal mucosa after ovalbumin treatment. These may contribute to the translocation of high mobility group box 1 and the development of allergic rhinitis.

© 2021 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier Editora Ltda. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Introduction

Allergic rhinitis (AR) is defined as a type of nasal mucosa inflammation associated with an IgE-mediated immune response against allergens.¹ Patients with AR are usually characterized by symptoms of nasal obstruction, rhinorrhea, sneezing and nasal itching.² The disorder also causes a considerable burden to patients, affecting their quality of life, cognitive function, and self-perception.³ Nowadays, AR has become an important worldwide public health problem affecting 10%–20% of the adult population.⁴ Understanding the nature of AR will improve the care of patients suffering from this disorder.

It is widely accepted that high mobility group box 1 (HMGB1), a ubiquitously-expressed protein, plays multiple roles in physiological and pathological processes.⁵ HMGB1 was originally described as an important chromatin protein,⁶ but is now known to have different functions based on compartment-specific expression.⁷ When HMGB1 is released into an extracellular location, it mediates activation of the innate immune response as a pro-inflammatory factor.⁸ Our previous study demonstrated that HMGB1 increased in the nasal mucosa and trans-located after ovalbumin (OVA) exposure in a murine AR model. Inhibition of HMGB1 by ethyl pyruvate exerted a therapeutic effect on AR.⁹ However, the mechanism of HMGB1 release in AR remains unclear.

HMGB1 can be passively released from dying cells,¹⁰ as well as being actively secreted by inflammatory cells such as macrophages, monocytes, dendritic cells, and natural killer cells.¹¹ Numerous pathways have been demonstrated to be implicated in the release of HMGB1, such as double-stranded RNA-activated protein kinase (PKR)-mediated inflammasome activation,¹² and chromosome region maintenance 1-mediated nuclear translocation.¹³ Recently, a series of studies revealed that caspase-1 could act as a potential therapeutic target in AR using various protective agents,^{14–16} suggesting that the inflammasome may be activated after allergen exposure. Activation of the inflammasome leads to pyroptosis and results in cell death,¹⁷ which then mediates HMGB1 release.¹⁸ However, there is a lack of research into which the subfamily of inflammasome is activated in AR. Assembly of an inflammasome complex is initiated by nucleotide-binding domain, leucine-rich repeat receptor (NLR) or absent in melanoma 2 (AIM2) after recognizing pathogen-associated molecular patterns (PAMPs) or danger-associated molecular patterns (DAMPs).¹⁹ Activated NLRs or AIM2 can recruit apoptosis-associated speck-like protein containing a caspase-recruitment domain (ASC) to engage caspase-1 activation.²⁰ Nlrp3 and AIM2 have been demonstrated to be up-regulated in the pathogen-

esis of upper airway disease such as acute and chronic rhinosinusitis.^{21,22}

We hypothesized that the inflammasome is activated in the nasal mucosa of mice by exposure to OVA, and that pyroptosis may occur after inflammasome activation. To test this hypothesis, we established a mouse AR model and examined activation of the inflammasome in AR.

Methods

Animals

Twenty wild-type male BALB/c mice aged from 6 to 8 weeks were involved in the study. The animals were housed in a specific pathogen-free animal facility. These mice were randomly divided into two groups – control group and AR group – with 10 mice in each group. Six mice from each group were used for analysis of protein expression, and the remaining mice were used for histological observation and immunohistochemistry. The experiments were conducted according to the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee (IACUC Number: S2372).

Establishment of a murine allergic rhinitis model

The establishment of mouse AR was performed as previously described.⁹ The experimental group was injected intraperitoneally on the first, 8th, and 15th days of the study with 200 μ L PBS solution containing 40 μ g OVA (grade V; Sigma-Aldrich; St. Louis, MO, USA) and 2 mL aluminum hydroxide, while the control group was only given the same amount of PBS solution. From day 22, 500 μ g OVA in 20 μ L PBS was inhaled into the bilateral nasal cavities through normal breathing daily for one week (Fig. 1) in the AR group, while the control group received saline alone.

Histological observation and immunohistochemistry

Four mice from each group were used for analysis of activation of the inflammasome and HMGB1 localization. The mice were humanely killed after anesthesia and immediately decapitated. The snouts were fixed with 4% formaldehyde overnight, decalcified with 10% ethylenediaminetetraacetic acid-2 Na in PBS for one month, dehydrated in a graded ethanol series and then embedded in paraffin. Finally, the samples were sectioned at 5 μ m and collected.

Figure 1 Establishment of a murine model of Allergic Rhinitis (AR). Mice in the AR group were sensitized by intraperitoneal (IP) injection of 40 μ g OVA and 2 μ g aluminum on experimental days 1, 8, and 15, and were challenged with OVA by daily inhalation (ID) from days 22 to 28 (A). H&E staining and AB-PAS staining were performed to observe the eosinophilic infiltration and goblet cell hyperplasia. Evident infiltration of eosinophils (red arrows) and increased numbers of goblet cells (black arrows) were observed in the AR group (B) compared with the control group.

TdT-mediated dUTP nick end labeling (TUNEL)

Western blot analysis

using RIPA lysis buffer and protein concentrations were measured by BCA assay. Protein lysates were separated on 12% Sodium Dodecyl Sulfate (SDS) – Polyacrylamide gels and transferred to Polyvinylidene Difluoride (PVDF) membranes. The membranes were blocked for 1 h with 5% fat-free milk in Tris-Buffered Saline containing Tween (TBST) and incubated overnight at 4°C with the appropriate dilution of primary antibodies: anti-Nlrp3 (R&D Systems, Minneapolis, MN, USA, diluted 1:300), anti-AIM2 (Abcam, Cambridge, MA, USA, diluted 1:1,000), anti-Asc (Abcam, diluted 1:1,000), anti-caspase-1 (Biovision, Milpitas, CA, USA, 1:200), and anti- β -actin (Millipore, Billerica, MA, USA, diluted 1:3,000). After washing, the membranes were incubated for 1 h at room temperature with the appropriate HRP-conjugated secondary antibody (diluted 1:3,000). The protein bands were visualized by BeyoECL Plus (Beyotime, Haimen, Jiangsu, China), and Gel-Pro analyzer 4.0 software (Media Cybernetics, Inc., Rockville, MD, USA) was used for relative quantification, with β -actin as the internal control.

Statistical analysis

All results are expressed as mean $\pm$ SD. Statistical analysis was performed using the statistical package for the social sciences (SPSS Version 18.0; SPSS Inc., Chicago, IL, USA). Student's *t*-test was used to analyze the expression of inflammasome components. A value of $p < 0.05$ was considered statistically significant.

Results

Establishment of a murine AR model

H&E staining showed that numerous eosinophils infiltrated the nasal mucosa of AR mice, while no evident inflammatory cells were observed in that of control mice (Fig. 1). Furthermore, goblet cell hyperplasia was also observed in AR mice.

Activation of the AIM2 inflammasome

To detect alterations in expression of inflammasome components in the OVA-induced airway response, we observed the localization and expression of inflammasome components using immunohistochemistry and western blotting. The expressions of AIM2, asc, and cleaved caspase-1 were all significantly increased after OVA exposure (Figs. 2 and 3).

Pyroptosis but not apoptosis may occur after OVA stimulation

HMGB1 may be passively released as a result of cell pyroptosis. We detected DNA fragments using TUNEL and confirmed cleavage of caspase-3 and PARP-1. Increased numbers of TUNEL-positive cells were found in the AR group, whereas no differences in cleavage of caspase-3 or PARP-1 were observed between the two groups. The translocation of HMGB1 was observed in the AR group as a result of inflammasome activation (Fig. 4).

Discussion

We successfully established an OVA-induced murine model of AR, which is characterized by Th2-dominated airway inflammation. Eosinophilia and goblet cell hyperplasia were found in the nasal mucosa of AR mice. In addition, significantly increased activation of AIM2 inflammasomes was found in the AR mice, where cytoplasmic transfer and up-regulation of HMGB1 were also observed.

In this study, we demonstrate activation of the AIM2 inflammasome in the nasal mucosa in AR. AIM2 has been found to act as a DNA sensor in innate immunity. Upon sensing cytosolic DNA, including bacterial, viral²³ and host,²⁴ the AIM2 protein recruits the adaptor protein ASC through the PYRIN-PAAD-DAPIN (PYD) domain and the ASC protein recruits procaspase-1 through the caspase activation and recruitment domain (CARD) to form an active AIM2 inflammasome. Our results showed that the components of the AIM2 inflammasome including AIM2, asc, and cleaved caspase-1 were up-regulated after OVA exposure in the nasal mucosa, suggesting that the AIM2 inflammasome was activated in murine AR. Recently, an interesting study carried out on the eosinophil extracellular traps showed that extracellular DNA concentrations in bronchoalveolar lavage of OVA-treated mice were significantly increased compared with controls.²⁵ This result suggested that eosinophils may contribute to activation of the AIM2 inflammasome in AR. Furthermore, we analyzed cell death using the TUNEL assay in nasal mucosa and demonstrated an increase in cell death in the nasal sections of OVA- versus saline-treated animals. We also observed cleavage of caspase-3 and PARP-1, which are characteristic of apoptosis, in the nasal mucosa after OVA exposure. However, there is no evidence that cleavage of caspase-3 and PARP-1 occurred in the nasal mucosa after OVA stimulation. During pyroptosis, cells undergo chromosomal DNA cleavage and nuclear condensation and become positive in the TUNEL assay,²⁶ but without the cleavage of typical caspase substrates such as caspase-3 and PARP that are characteristic of apoptosis.²⁷ Therefore, we concluded that pyroptosis occurred in the nasal mucosa of our murine AR model. HMGB1 release can occur downstream of inflammasome formation and caspase-1 activation. Consistent with our previous finding, HMGB1 was released into the cytosol and extracellular space after OVA exposure. Released HMGB1 may induce and amplify AR. Thus, activation of the AIM2 inflammasome may induce HMGB1 translocation in AR.

Nlrp3 is the most studied structural subset of the inflammasome and plays an important role in the pathogenesis of numerous airway diseases such as asthma and acute lung injury.²⁸ In our study, we found that Nlrp3 was down-regulated in nasal mucosa from the AR group compared to the control group. An interesting study comparing the expression of NLRs in nasal biopsies from healthy individuals and patients suffering from intermittent AR showed that Nlrp3 was significantly lower in the allergic group, especially during pollen season, than among the healthy group.²⁹ In another study using a murine asthma model, decreased expression of Nlrp3 was also found during airway inflammation.³⁰ These results indicated that Nlrp3 may be down-regulated after allergen exposure as a defense mech-




Figure 2 Expression of components of the inflammasome after OVA stimulation. The expressions of two receptors, Nlrp3 and AIM2, were analyzed by western blotting. The expression of Nlrp3 decreased whereas AIM2 increased in the nasal mucosa after OVA exposure, $p < 0.01$. Meanwhile the expression of another component of the inflammasome complex, Asc, and the levels of cleaved caspase-1 were both increased, $p < 0.05$ and 0.01 , respectively (* $p < 0.01$, ** $p < 0.05$).




Figure 3 Expression of AIM2, caspase-1, and HMGB1 in the nasal mucosa of mice. AIM2 and caspase-1 were rarely expressed in the nasal mucosa from the control group (A, C). However, after OVA stimulation, the expression of both proteins was up regulated in the epithelium, lamina propria, and infiltrated inflammatory cells (B, D). HMGB1 was abundantly expressed in the epithelium and lamina propria, and mainly located in the nucleus in mucosa from control mice (E). The expression of HMGB1 significantly increased in the nasal mucosa of AR mice and the translocation of HMGB1 from the nucleus to the cytoplasm was observed (F, red arrows).

anism. Furthermore, the effects of Th2 cytokines such as IL-4 and IL-13 on the expression of Nlrp3 were studied on human keratinocytes, THP-1 cells and mouse bone marrow-derived macrophages.^{31,32} The research demonstrated that expression of Nlrp3 was suppressed by treatment with Th2

cytokines. Th2-dominated airway inflammation is one characteristic of AR, and Th2 cytokines such as IL-4, -5, and -13 are released after allergen stimulation.³³ Therefore, the expression of Nlrp3 may be suppressed by Th2 cytokines in AR.




Figure 4 Pyroptosis but not apoptosis may occur in murine Allergic Rhinitis (AR). TUNEL assay revealed that fragmentation of DNA significantly increased in the nasal mucosa of mice in the AR group. However, there was no evident cleavage of caspase-3, and no PARP-1 was found in the AR group.

In our study, we demonstrated that the AIM2 inflammasome was activated in AR and may contribute to the release of HMGB1. During airway inflammation, numerous cell types participated in the development of AR, such as Th2 cells. Recently, a study on the role of Nlrp3 in Th2 differentiation revealed that it is expressed by CD4⁺ T-cells and acts as a key transcription factor.³⁴ Thus Nlrp3 may be implicated in the pathogenesis of Th2-dominated diseases such as AR and asthma. However, a major limitation of our study is that the mucosa is a complex organ comprised of numerous tissues. It is difficult to show changes in protein expression of Nlrp3 at the level of a single cell type in the nasal mucosa. The role of Nlrp3 in AR thus warrants further study.

Conclusion

In conclusion, we demonstrated that the AIM2 inflammasome was activated and pyroptosis may occur in the nasal mucosa after OVA treatment. The release of HMGB1 was also observed. Activation of the inflammasome may contribute to the translocation of HMGB1 and the development of AR. Caspase-1 may therefore act as a potential therapeutic target for AR.

Funding

This study was supported by the Wu Jieping Medical Foundation (no. LC1345) and The Natural Science Foundation of Hubei Province, China (no. 2014CFB359).

Conflicts of interest

The authors declare no conflicts of interest.

References

1. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European Position Paper on rhinosinusitis and nasal polyps 2020. *Rhinology*. 2020;58:1–464.
2. Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonner JR, et al. Clinical practice guideline: allergic rhinitis. *Otolaryngol Head Neck Surg*. 2015;152:S1–43.
3. Fineman SM. The burden of allergic rhinitis: beyond dollars and cents. *Ann Allergy Asthma Immunol*. 2002;88:2–7.
4. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. *J Allergy Clin Immunol*. 2010;126:466–76.
5. Kang R, Chen R, Zhang Q, Hou W, Wu S, Cao L, et al. HMGB1 in health and disease. *Mol Aspects Med*. 2014;40:1–116.
6. Stros M. HMGB proteins: interactions with DNA and chromatin. *Biochim Biophys Acta*. 2010;1799:101–13.
7. Yang H, Antoine DJ, Andersson U, Tracey KJ. The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. *J Leukoc Biol*. 2013;93:865–73.
8. Yang H, Tracey KJ. Targeting HMGB1 in inflammation. *Biochim Biophys Acta*. 2010;1799:149–56.
9. Chen S, Wang Y, Gong GQ, Chen JJ, Niu YZ, Kong WJ. Ethyl pyruvate attenuates murine allergic rhinitis partly by decreasing high mobility group box 1 release. *Exp Biol Med*(Maywood). 2015;240:1490–9.
10. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. *Nature*. 2002;418:191–5.
11. Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. *Nat Rev Rheumatol*. 2012;8:195–202.
12. Lu B, Nakamura T, Inouye K, Li J, Tang Y, Lundback P, et al. Novel role of PKR in inflammasome activation and HMGB1 release. *Nature*. 2012;488:670–4.
13. Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. *EMBO J*. 2003;22:5551–60.
14. Kim KY, Nam SY, Shin TY, Park KY, Jeong HJ, Kim HM. Bamboo salt reduces allergic responses by modulating the caspase-1 activation in an OVA-induced allergic rhinitis mouse model. *Food Chem Toxicol*. 2012;50:3480–8.
15. Oh HA, Kim HM, Jeong HJ. Beneficial effects of chelidonic acid on a model of allergic rhinitis. *Int Immunopharmacol*. 2011;11:39–45.
16. Oh HA, Han NR, Kim MJ, Kim HM, Jeong HJ. Evaluation of the effect of kaempferol in a murine allergic rhinitis model. *Eur J Pharmacol*. 2013;718:48–56.
17. Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. *Nat Rev Microbiol*. 2009;7:99–109.
18. Lamkanfi M, Sarkar A, Vande Walle L, Vitari AC, Amer AO, Wewers MD, et al. Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. *J Immunol*. 2010;185:4385–92.
19. Schroder K, Tschopp J. The inflammasomes. *Cell*. 2010;140:821–32.
20. Fernandes-Alnemri T, Wu J, Yu JW, Datta P, Miller B, Jankowski W, et al. The pyroptosome: a supramolecular assembly of ASC

- dimers mediating inflammatory cell death via caspase-1 activation. *Cell Death Differ.* 2007;14:1590–604.
21. Wang YJ, Gong GQ, Chen S, Xiong LY, Zhou VV, Huang X, et al. NLRP3 inflammasome sequential changes in *Staphylococcus aureus*-induced mouse model of acute rhinosinusitis. *Int J Mol Sci.* 2014;15:15806–20.
22. Jardeleza C, Miljkovic D, Baker L, Boase S, Tan NC, Koblar SA, et al. Inflammasome gene expression alterations in *Staphylococcus aureus* biofilm-associated chronic rhinosinusitis. *Rhinology.* 2013;51:315–22.
23. Burckstummer T, Baumann C, Bluml S, Dixit E, Durnberger G, Jahn H, et al. An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. *Nat Immunol.* 2009;10:266–72.
24. Jakobs C, Perner S, Hornung V. AIM2 drives joint inflammation in a self-DNA triggered model of chronic polyarthritis. *PLoS One.* 2015;10:e0131702.
25. Cunha AA, Porto BN, Nunez NK, Souza RG, Vargas MH, Silveira JS, et al. Extracellular DNA traps in bronchoalveolar fluid from a murine eosinophilic pulmonary response. *Allergy.* 2014;69:1696–700.
26. Brennan MA, Cookson BT. Salmonella induces macrophage death by caspase-1-dependent necrosis. *Mol Microbiol.* 2000;38:31–40.
27. Bergsbaken T, Cookson BT. Macrophage activation redirects yersinia-infected host cell death from apoptosis to caspase-1-dependent pyroptosis. *PLoS Pathog.* 2007;3:e161.
28. Lee S, Suh GY, Ryter SW, Choi AM. Regulation and function of the nucleotide binding domain leucine-rich repeat-containing receptor, pyrin domain-containing-3 inflammasome in lung disease. *Am J Respir Cell Mol Biol.* 2016;54:151–60.
29. Bogefors J, Rydberg C, Uddman R, Fransson M, Mansson A, Benson M, et al. Nod1, Nod2 and Nalp3 receptors, new potential targets in treatment of allergic rhinitis? *Allergy.* 2010;65:1222–6.
30. Tran HB, Lewis MD, Tan LW, Lester SE, Baker LM, Ng J, et al. Immunolocalization of NLRP3 inflammasome in normal murine airway epithelium and changes following induction of ovalbumin-induced airway inflammation. *J Allergy (Cairo).* 2012;2012:819176.
31. Hwang I, Yang J, Hong S, Ju Lee E, Lee SH, Fernandes-Alnemri T, et al. Nontranscriptional regulation of NLRP3 inflammasome signaling by IL-4. *Immunol Cell Biol.* 2015;93:591–9.
32. Niebuhr M, Baumert K, Heratizadeh A, Satzger I, Werfel T. Impaired NLRP3 inflammasome expression and function in atopic dermatitis due to Th2 milieu. *Allergy.* 2014;69:1058–67.
33. Pawankar R, Okuda M, Yssel H, Okumura K, Ra C. Nasal mast cells in perennial allergic rhinitis exhibit increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells. *J Clin Invest.* 1997;99:1492–9.
34. Bruchard M, Rebe C, Derangere V, Togbe D, Ryffel B, Boidot R, et al. The receptor NLRP3 is a transcriptional regulator of TH2 differentiation. *Nat Immunol.* 2015;16:859–70.